EquityFolio

BMEA

NASDAQ Healthcare

Biomea Fusion, Inc.

$0.49

-$0.03 (-6.17%)

Live quote

52w: $0.46 – $2.24

Loading chart…
P/E Ratio—
P/B Ratio4.68
EV/EBITDA—
Debt/Equity—
ROE-814.62%
ROIC—
Revenue Growth—
Gross Margin—
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Own BMEA? Track it here.

Create a free account to add BMEA to a portfolio and watch your P/L update in real time.

Custom screens, valuation models and backtesting are coming to Pro.

Create a free account